Detalhe da pesquisa
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447003
2.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32339253
3.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776843
4.
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
Leuk Lymphoma
; 57(6): 1482-6, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26414189
5.
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
Leuk Lymphoma
; 57(1): 226-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-25947035